Dr. Vicken Karageozian was born in Pasadena, California and raised in Laguna Hills. He graduated among the top of his class from the University of California, San Diego in 1991 with degrees in biochemistry, cellular biology, and economics. In 1995, Dr. Karageozian received his medical degree from Tufts University School of Medicine in Boston, where he also ranked in the top of his class. After completing an internship at UCLA, he began his ophthalmology residency at the University of Irvine in 2000. He was elected to the distinguished position of chief of residents during the same year.
Dr. Karageozian is a diplomat of the American Board of Ophthalmology and Association for Research in Vision and Ophthalmology, as well as a member of the California Medical Association and the Orange County Ophthalmologic Society. He also teaches cataract surgery to residents at the UCI School of Medicine Department of Ophthalmology as an Assistant Clinical Professor of Ophthalmology.
Dr. Karageozian’s position is unique in that he is an innovator both on the clinical and surgical fronts as well as extensively in the research arena. Dr. Karageozian has co-founded two biotech companies responsible for developing innovative treatments for several medical eye conditions that have few treatment options, including early diabetic retinopathy, glaucoma-related vision loss, retinitis pigmentosa, and adjuncts to vitrectomy surgery. His work on retinal diseases of the eye, including vitreous hemorrhage and diabetic retinopathy, has been published in many peer review journals. He has presented his work at the American Academy of Ophthalmology, the National Institutes of Health, the Association for Research in Vision and Ophthalmology, and before the United States Food and Drug Administration.
Currently, Dr. Karageozian divides his time between surgery, his clinical practice, and the drug development efforts he has spearheaded. In 2001, Dr. Karageozian co-founded the pharmaceutical research company, Vitreo-Retinal Technologies, Inc. to further develop his work in the area of retinal diseases.